KRAS and cancer: Steckel et al. initially demonstrated that transcription factor GATA2 is requisite for KRAS oncogene-dependent cancer cells through RNAi assay.63 Because there is no clinical targeted drug for GATA2, the downstream regulatory pathways of GATA2 were studied.